NCT07357012 A Smart Wearable Device for Monitoring Urination Function in Benign Prostatic Hyperplasia
| NCT ID | NCT07357012 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Benign Prostatic Hyperplasia |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2026-02-01 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Benign Prostatic Hyperplasia (BPH) is a common condition that can cause bothersome urination problems and reduce quality of life. Accurately measuring how the bladder empties is important for diagnosis and treatment, but current methods like uroflowmetry can be inconvenient and are done only at a clinic. This study aims to test a new, non-invasive smart wearable device that uses Electrical Impedance Tomography (EIT) to monitor bladder function in patients with BPH. The device is worn on the lower abdomen. In this study, participants will use this EIT device while also undergoing the standard uroflowmetry test. The main goal is to see how well the measurements from the new device (like urine flow rate and volume) agree with those from the standard test. The study hopes to show that this wearable device can accurately and comfortably track bladder function over time. If successful, it could lead to a new tool for doctors to better monitor patients with BPH, even potentially at home.
Eligibility Criteria
Inclusion Criteria: Patients with BPH who need urodynamic tests to further evaluate the underlying pathophysiology of LUTS prior to invasive treatment. Patients who understand and agree with the written informed consent, and voluntary to participate in the study. Exclusion Criteria: Patients with catheter-dependent urinary retention. Patients who cannot void \> 150ml. Patients with uncontrolled acute urinary tract infections. Patients who suffer from severe mental illness or other diseases that may affect judgment or cooperation during the study. Patients with implanted cardiac pacemaker or other electronic implants that may potentially be interfered by the EIT device. Patients with other conditions who are deemed unsuitable for participation by the investigator.
Contact & Investigator
Liu Zhuo
PRINCIPAL INVESTIGATOR
Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT07357012 clinical trial?
This trial is open to male participants only, studying Benign Prostatic Hyperplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07357012 currently recruiting?
Yes, NCT07357012 is actively recruiting participants. Contact the research team at 2511110553@bjmu.edu.cn for enrollment information.
Where is the NCT07357012 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China.
Who is sponsoring the NCT07357012 clinical trial?
NCT07357012 is sponsored by Peking University Third Hospital. The principal investigator is Liu Zhuo at Peking University Third Hospital. The trial plans to enroll 40 participants.